News stories about Ardelyx (NASDAQ:ARDX) have been trending somewhat positive this week, according to Accern. The research firm scores the sentiment of press coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Ardelyx earned a coverage optimism score of 0.22 on Accern’s scale. Accern also gave news stories about the biopharmaceutical company an impact score of 47.2303863035963 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near term.
Here are some of the news stories that may have effected Accern Sentiment Analysis’s rankings:
- Technical Indicators under Review – Ardelyx Inc (NASDAQ: ARDX) (stockspen.com)
- Ardelyx, Inc. (NASDAQ:ARDX) – Market Cap Secrets (nasdaqjournal.com)
- An Eye on Data – Ardelyx Inc (NASDAQ: ARDX) (stocksmarketcap.com)
- Global Irritable Bowel Syndrome Treatment Market Analysis 2017-2026: Ironwood Pharmaceuticals , Ardelyx , Novartis … (factsweek.com)
- Hair-Raising Facts to Know About Average True Range (ATR) – Ardelyx (NASDAQ:ARDX) (thestockgem.com)
Shares of Ardelyx stock traded up $0.05 during trading hours on Thursday, hitting $5.15. The company’s stock had a trading volume of 360,522 shares, compared to its average volume of 295,299. Ardelyx has a twelve month low of $4.05 and a twelve month high of $14.10. The firm has a market cap of $238.02, a PE ratio of -3.79 and a beta of 0.79.
A number of brokerages have issued reports on ARDX. BidaskClub lowered shares of Ardelyx from a “buy” rating to a “hold” rating in a report on Friday, February 2nd. Zacks Investment Research downgraded Ardelyx from a “buy” rating to a “hold” rating in a research report on Friday, February 2nd. Cantor Fitzgerald set a $12.00 price target on Ardelyx and gave the stock a “buy” rating in a research report on Monday, February 12th. Leerink Swann restated an “outperform” rating and set a $13.00 price target on shares of Ardelyx in a research note on Monday, March 19th. Finally, Wedbush reissued an “outperform” rating on shares of Ardelyx in a report on Thursday, March 15th. Three investment analysts have rated the stock with a sell rating and six have assigned a buy rating to the stock. The stock has an average rating of “Hold” and an average target price of $12.93.
Ardelyx Company Profile
Ardelyx, Inc is a clinical-stage biopharmaceutical company. The Company’s therapeutics focuses on addressing cardiorenal and gastrointestinal (GI) diseases. It operates through the research, development and commercialization of biopharmaceutical products segment. The Company’s products line includes cardiorenal portfolio and gastrointestinal portfolio.
Receive News & Ratings for Ardelyx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ardelyx and related companies with MarketBeat.com's FREE daily email newsletter.